CAV1 and cancer: Indeed, BRAFV600E/p53R172H double-mutant organoids displayed higher CAV1 expression than the BRAFV600E single-mutants (Fig. 1b, c; Supplementary Fig. S3e), which is in line with its reported role in mediating anoikis resistance in several cancer entities [66–68].